Risk factors for venous thromboembolism and prophylaxis in medical inpatients: Data from the FADOI "GEMINI" study;Fattori di rischio per tromboembolismo venoso e profilassi nei pazienti ricoverati in Medicina Interna: Analisi dallo studio FADOI "GEMINI"

Italian Journal of Medicine

Volumn 4, Issue 1, 2010, Pages 23-31

  Campanini, Mauro ^a   Gussoni, Gualberto ^b   Silingardi, Mauro ^c   Scannapieco, Gianluigi ^d   Buniolo, Cario ^e   Valerio, Antonella ^b   Ageno, Walter ^f   Lori, Ido ^c   Mazzone, Antonino ^g  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b Fondazione FADOI   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d OSPEDALE CA FONCELLO   (Italy)

^e QßGroup SpA   (Italy)

^f UNIVERSITY OF INSUBRIA   (Italy)

^g Ospedale Civile di Legnano   (Italy)

Author keywords

Internal medicine; Prophylaxis; Risk factors; Thromboembolism; Venous

Indexed keywords

FIBRINOLYTIC AGENT;

AGED; ARTICLE; BED REST; BIOASSAY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SYMPTOM; THROMBOSIS PREVENTION; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

EID: 77950863123     PISSN: 18779344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.itjm.2010.01.002     Document Type: Article

References (45)

1. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
2. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton 3rd LI. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160(6):809-815
3. Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost 2004; 2(12):2156-2161 (Pubitemid 40185776)
4. Millar JA. Selection of medical patients for prophylaxis of venous thromboembolism based on analysis of the benefithazard ratio. Intern Med J 2009; 39(9):606-612
5. Oger E, Eressolette L, Nonent M, Lacut K, Guias B, Couturaud F, et al. High prevalence of asymptomatic deep vein thromhosis on admission in a medical unit among elderly patients. The TADEUS Project. Thromb Haemost 2002; 88:592-597 (Pubitemid 35174000)
6. Goldhaber SZ, Tapson VF, DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasoundconfirmed deep vein thrombosis. Am J Cardiol 2004; 93(2): 259-262
7. Samama MM, Cohen TA, Darmon J-Y, Desjardins L, Eldor A, Janhon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341:793-800. (Pubitemid 29420474)
8. Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. Am J Respir Crit Care Med 2000; 161:1109-1114 (Pubitemid 30243816)
9. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110(7):874-879 (Pubitemid 39096017)
10. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al., ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placeho controlled trial. Br Med J 2006; 332:325-329
11. Lowe GD, Sandercock PA, Rosendaal FR. Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance? Lancet 2003; 362(9383):504-505
12. Gussoni G, Campanini M, Silingardi M, Scannapieco G, Mazzone A, Magni G, et al., GEMINI Study Group. In-hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in internal medicine. Findings from a multicenter, prospective study. Thromb Haemost 2009; 101:893-901.
13. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray GC. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:338S-400S.
14. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical-outcome based prospective study on venous thromboembolism after cancer surgery - The SRISTOS project. Ann Surg 2006; 243:89-95. (Pubitemid 43054059)
15. Schuurman B, den Heijer M, Nijs AM. Thrombosis prophylaxis in hospitalised medical patients: does prophylaxis in all patients make sense? Neth J Med 2000;56(5):171-176
16. Arcelus JI, Candocia S, Traverso CI, Fabrega F, Caprini JA, Hasty JH. Venous thromboembolism prophylaxis and risk assessment in medical patients. Semin Thromb Hemost 1991; 17(Suppl 3): 313-318
17. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992; 305(6853):567-574
18. Lutz L. Venous thromboembolism in internal medicine: risk assessment and pharmaceutical prophylaxis. Die Med Welt 2002; 53:231-234 (Pubitemid 34982622)
19. Haas SK. Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb Hemost 2002; 28(6):577-584
20. Cohen AT, Alikhan R, Arcelus JJ, Bergmann JF, Haas S, Merli JG, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb haemost 2005; 94:750-759
21. Falanga A. The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. Cancer Invest 2009; 27(1):105-115
22. lmherti D, Agnelli G, Ageno W, Moia M, Palareti G, Pistelli G, et al. Clinical characteristics and management of cancerassociated acute venous thromboembolism findings from the MASTER Registry. Haematologica 2008; 93:273-278
23. Kahn SR, Panju A, Geerts W, GF, Desjardins L, Turpie AG et al. for the CURVE Investigators. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients. Thromb Res 2007; 119:145-155
24. Jubelirer SJ, Reyes B, Boce M, Elhabyan AK, Mimnagh K, Rosencrance JG, et al. Pharmacologic thromboembolic prophylaxis for medical patients in a tertiary care, teaching community hospital: room for improvement. W V Med J 2008; 104:10-14
25. Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes Al, Rea DW, et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (W ARP): an open-label randomised trial. Lancet 2009; 373:567-574
26. Agnelli G, Gussoni G, Bianchini C, Verso M, Mándala M, Cavanna L, et al., PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo controlled, double-blind study. Lancet Oncol 2009;10(10):943-949
27. Silverstein MC, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1998; 158:585-593
28. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al., MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness. Analysis of the MEDENOX Study. Arch lnt Med 2004; 164:963-968
29. Anderson Jr FA, Wheeler HB, Goldberg RJ, Hosmer DW, Pathwardan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med 1991;151:933-938
30. Weill-Engcrer S, Meaume S, Lahlou A, Piette F, Saint-Jean O, Sachet A, et al. Risk factors for deep vein thrombosis in inpatients aged 65 and older a case-control multicenter study. J Am Geriatr Soc 2004; 52:1299-1304 (Pubitemid 39038202)
31. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160(22):3415-3420
32. Alikhan R, Spyropoulos AC. Epidemiology of venous thromboembolism in cardiorespiratory and infectious disease. Am J Med 2008; 121(11):935-942
33. Cohen AT, Tapson VF, Bergmann J-F, Goldhaber SZ, Kakkar AK, Deslandes B, et al., ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational, cross-sectional study. Lancet 2008; 371:387-394
34. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism VTE in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98:756-764
35. Chopard P, Dorffler-Melly J, Hess U, Wuillemin WA, Hayoz D, Gallino A, et al. Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement. J Intern Med 2005; 257:352-357 (Pubitemid 40461188)
36. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, THE-PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003; 145(4): 614-621 (Pubitemid 36403489)
37. Spyropoulos AC. Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients. Chest 2005; 128(2):958-969 (Pubitemid 41140532)
38. Hirsh J, Raschke R. Heparin and low-motecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):188-203S. (Pubitemid 39297954)
39. Mahè I, Aghassarian M, Drouet L, Bal Dit-Sollier C, Lacut K, Heilmann JJ, et al. Tinzaparin and enoxaparin given at prophylactic doses for eight days in medical elderly patients with impaired renal function. A comparative pharmacokinetic study. Thromb Haemost 2007; 97:581-586
40. Dentali F, Riva N, Gianni M, Malato A, Bozzato S, Bemasconi M, et al. Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increate risk of venous thromboembolic events. Thromb Res 2008; 123:67-71.
41. Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecularweight heparin dalteparin. An assessment of safety and pharmacodynamics: the DIRECT Study. Arch Intern Med 2008;168: 1805-1812
42. Labarere J, Bosson JL, Brion JP, Fabre M, lmbert B, Carpentier P, Pernod G, et al. Validation of a clinical guideline on prevention of venous thromboembolism in medical inpatients a before-andafter study with systematic ultrasound examination. J Intern Med 2004; 256:338-348 (Pubitemid 39304346)
43. Dobesh PP, Stacy ZA. Effect of a clinical pharmacy education program on improvement in the quantity and quality of venous thromboembolism prophylaxis for medically ill patients. J Manag Care Pharm 2005; 11(9):755-762
44. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007; 167(14):1471-1475
45. Goldhaber SZ. Outpatient venous thromboembolism: a common but often preventable public health threat. Arch Intern Med 2007; 167(14):1451-1452